Tags

Type your tag names separated by a space and hit enter

CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease.
Rheumatology (Oxford). 2012 Dec; 51(12):2141-5.R

Abstract

OBJECTIVE

To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to and clinical expression of Behçet's disease (BD) in a cohort of Italian patients.

METHODS

One hundred and ninety-six consecutive Italian patients satisfying the ISG criteria for BD were followed up for 8 years, and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the CCR5Δ32 polymorphism. A standard microlymphocytotoxicity technique was used to serotype HLA-B51. The patients were subgrouped on the basis of the presence or absence of clinical manifestations.

RESULTS

The distribution of the CCR5Δ32 genotype differed between BD patients and controls (P = 0.02). The CCR5Δ32 allele was more common in BD patients than in controls [P = 0.02, odds ratio (OR) 2.28 (95% CI 1.1, 4.8)]. Carriers of the CCR5Δ32 allele (Δ32/Δ32 + CCR5/Δ32) were significantly more common in BD patients than in controls [P = 0.02, OR 2.37 (95% CI 1.1, 5.1)]. Population-attributable risk was 7.1%. In categorizing patients according to gender, the association between CCR5Δ32 polymorphism and BD was similar in females and males (ORs 2.76 and 2.0, respectively). No significant differences were found when the frequencies of clinical manifestations were compared between CC5RΔ32 allele carriers and non-carriers.

CONCLUSION

CCR5Δ32 polymorphism is associated with an increased susceptibility to develop BD. Chemokines may have a role in the pathophysiology of BD.

Authors+Show Affiliations

Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22966075

Citation

Atzeni, Fabiola, et al. "CC Chemokine Receptor 5 Polymorphism in Italian Patients With Behcet's Disease." Rheumatology (Oxford, England), vol. 51, no. 12, 2012, pp. 2141-5.
Atzeni F, Boiardi L, Casali B, et al. CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. Rheumatology (Oxford). 2012;51(12):2141-5.
Atzeni, F., Boiardi, L., Casali, B., Farnetti, E., Nicoli, D., Sarzi-Puttini, P., Pipitone, N., Olivieri, I., Cantini, F., Salvi, F., La Corte, R., Triolo, G., Filippini, D., Paolazzi, G., & Salvarani, C. (2012). CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. Rheumatology (Oxford, England), 51(12), 2141-5. https://doi.org/10.1093/rheumatology/kes238
Atzeni F, et al. CC Chemokine Receptor 5 Polymorphism in Italian Patients With Behcet's Disease. Rheumatology (Oxford). 2012;51(12):2141-5. PubMed PMID: 22966075.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. AU - Atzeni,Fabiola, AU - Boiardi,Luigi, AU - Casali,Bruno, AU - Farnetti,Enrico, AU - Nicoli,Davide, AU - Sarzi-Puttini,Piercarlo, AU - Pipitone,Nicolò, AU - Olivieri,Ignazio, AU - Cantini,Fabrizio, AU - Salvi,Fabrizio, AU - La Corte,Renato, AU - Triolo,Giovanni, AU - Filippini,Davide, AU - Paolazzi,Giuseppe, AU - Salvarani,Carlo, Y1 - 2012/09/09/ PY - 2012/9/12/entrez PY - 2012/9/12/pubmed PY - 2013/2/5/medline SP - 2141 EP - 5 JF - Rheumatology (Oxford, England) JO - Rheumatology (Oxford) VL - 51 IS - 12 N2 - OBJECTIVE: To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to and clinical expression of Behçet's disease (BD) in a cohort of Italian patients. METHODS: One hundred and ninety-six consecutive Italian patients satisfying the ISG criteria for BD were followed up for 8 years, and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the CCR5Δ32 polymorphism. A standard microlymphocytotoxicity technique was used to serotype HLA-B51. The patients were subgrouped on the basis of the presence or absence of clinical manifestations. RESULTS: The distribution of the CCR5Δ32 genotype differed between BD patients and controls (P = 0.02). The CCR5Δ32 allele was more common in BD patients than in controls [P = 0.02, odds ratio (OR) 2.28 (95% CI 1.1, 4.8)]. Carriers of the CCR5Δ32 allele (Δ32/Δ32 + CCR5/Δ32) were significantly more common in BD patients than in controls [P = 0.02, OR 2.37 (95% CI 1.1, 5.1)]. Population-attributable risk was 7.1%. In categorizing patients according to gender, the association between CCR5Δ32 polymorphism and BD was similar in females and males (ORs 2.76 and 2.0, respectively). No significant differences were found when the frequencies of clinical manifestations were compared between CC5RΔ32 allele carriers and non-carriers. CONCLUSION: CCR5Δ32 polymorphism is associated with an increased susceptibility to develop BD. Chemokines may have a role in the pathophysiology of BD. SN - 1462-0332 UR - https://www.unboundmedicine.com/medline/citation/22966075/CC_chemokine_receptor_5_polymorphism_in_Italian_patients_with_Behcet's_disease_ L2 - https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kes238 DB - PRIME DP - Unbound Medicine ER -